Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Barrios

Showing results (111-120 of 183) with videos related to

Pageof 19
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trialPaulo M Hoff, Daniel F Saragiotto, Carlos H Barrios, et al.
Microorganisms|August 26, 2023
Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19Marilou H Barrios, Suellen Nicholson, Rowena A Bull, et al.
CA: a Cancer Journal for Clinicians|February 19, 2020
Enhancing global access to cancer medicinesJavier Cortes, Jose Manuel Perez-García, Antonio Llombart-Cussac, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2022
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patientsMarion T van Mackelenbergh, Fenja Seither, Volker Möbus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of diseaseG Curigliano, X Hu, R Dent, et al.
British Journal of Cancer|July 1, 2015
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancerP A Jänne, I Smith, G McWalter, et al.
Journal of the National Cancer Institute|June 7, 2021
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast CancerHope S Rugo, Sherene Loi, Sylvia Adams, et al.
The New England Journal of Medicine|October 23, 2018
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerPeter Schmid, Sylvia Adams, Hope S Rugo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical TrialsMatthew P Smeltzer, Giorgio V Scagliotti, Heather A Wakelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.
Pageof 19

Showing results (111-120 of 183) with videos related to

Sort By:
Pageof 19
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 12, 2014
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trialPaulo M Hoff, Daniel F Saragiotto, Carlos H Barrios, et al.
Microorganisms|August 26, 2023
Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19Marilou H Barrios, Suellen Nicholson, Rowena A Bull, et al.
CA: a Cancer Journal for Clinicians|February 19, 2020
Enhancing global access to cancer medicinesJavier Cortes, Jose Manuel Perez-García, Antonio Llombart-Cussac, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2022
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patientsMarion T van Mackelenbergh, Fenja Seither, Volker Möbus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 4, 2026
Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of diseaseG Curigliano, X Hu, R Dent, et al.
British Journal of Cancer|July 1, 2015
Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancerP A Jänne, I Smith, G McWalter, et al.
Journal of the National Cancer Institute|June 7, 2021
PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast CancerHope S Rugo, Sherene Loi, Sylvia Adams, et al.
The New England Journal of Medicine|October 23, 2018
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerPeter Schmid, Sylvia Adams, Hope S Rugo, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2022
International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical TrialsMatthew P Smeltzer, Giorgio V Scagliotti, Heather A Wakelee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancerSuresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, et al.
Pageof 19